open access

Vol 48, No 3 (2010)
ORIGINAL PAPERS
Published online: 2010-11-13
Submitted: 2011-12-19
Get Citation

Biomarkers as prognostic factors in endometrial cancer.

Bożena Dobrzycka, Sławomir J Terlikowski
DOI: 10.2478/v10042-10-0061-8
·
Folia Histochem Cytobiol 2010;48(3):319-322.

open access

Vol 48, No 3 (2010)
ORIGINAL PAPERS
Published online: 2010-11-13
Submitted: 2011-12-19

Abstract

Endometrial cancer is the most common gynecologic malignancy in more developed countries. Approximately 75% of cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15-20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. The most common basis for determining the risk of recurrent disease has been classification of endometrial cancers into two subtypes. Type I, associated with a good prognosis and endometrioid histology and type II, associated with a poor prognosis and non-endometrioid histology. This review will focus primarily on the molecular biomarkers that have supported the dualistic model of endometrial carcinoma and help determine which patients would benefit from either adjuvant therapy or more aggressive primary treatment.

Abstract

Endometrial cancer is the most common gynecologic malignancy in more developed countries. Approximately 75% of cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15-20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. The most common basis for determining the risk of recurrent disease has been classification of endometrial cancers into two subtypes. Type I, associated with a good prognosis and endometrioid histology and type II, associated with a poor prognosis and non-endometrioid histology. This review will focus primarily on the molecular biomarkers that have supported the dualistic model of endometrial carcinoma and help determine which patients would benefit from either adjuvant therapy or more aggressive primary treatment.
Get Citation
About this article
Title

Biomarkers as prognostic factors in endometrial cancer.

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 48, No 3 (2010)

Pages

319-322

Published online

2010-11-13

DOI

10.2478/v10042-10-0061-8

Bibliographic record

Folia Histochem Cytobiol 2010;48(3):319-322.

Authors

Bożena Dobrzycka
Sławomir J Terlikowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl